Effectiveness of Rituximab in Pediatric OMS Patients.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00244361|
Recruitment Status : Completed
First Posted : October 26, 2005
Last Update Posted : May 10, 2011
The purpose of this study is to reduce the symptoms of OMS by testing rituximab (Rituxan®), to remove B lymphocytes that make antibodies and trigger brain inflammation. Evidence suggests that autoimmune brain inflammation causes the symptoms of OMS. This study of blood and spinal fluid intends to find out what effect rituximab has on OMS and on the spinal fluid B-cells.
Rituximab targets and destroys B-cells, which make antibodies that can attack the brain and cause may OMS. It is infused through a vein over a period of several hours. Rituximab has been used widely and studied extensively since its approval in 1997 by the U.S. Food and Drug Administration (FDA) for non-Hodgkin's B-cell Lymphoma (NHL). Today, more than 300,000 patients have received rituximab, and it is part of more than 200 completed, ongoing, or planned clinical trials. Rituximab is not FDA-approved for OMS.
|Condition or disease||Intervention/treatment||Phase|
|Opsoclonus-myoclonus Syndrome Opsoclonus Myoclonus Ataxia||Drug: rituximab||Phase 1 Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||25 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase I Clinical Trial of Rituximab for Pediatric Opsoclonus-Myoclonus Syndrome|
|Study Start Date :||June 2005|
|Primary Completion Date :||December 2007|
|Study Completion Date :||December 2007|
- Determine the effectiveness & selectivity of rituximab at depleting CSF B-cells in OMS with intrathecal B-cell expansion. This requires CSF & blood lympocyte immunophenotyping prior to the first infusion & intervals for 1 year after the final infusion.
- Evaluate the clinical efficacy & safety of rituximab by clinical assessments, scoring of videotapes for neurological severity, and various blood tests prior to the first infusion and then at one, three, six, and twelve months post the final infusion.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00244361
|United States, Illinois|
|National Pediatric Myoclonus Center, Department of Neurology, SIU School of Medicine, 751 N Rutledge St|
|Springfield, Illinois, United States, 62794|
|Principal Investigator:||Michael R Pranzatelli, M.D.||National Pediatric Neuroinflammation Organization, Inc.|